Common Stock, par value $0.0001

Arcus Biosciences, Inc.

3928 Point Eden Way, Hayward, CA, 94545

Item 5(a) of the Schedule 13D is hereby amended and restated to read as follows: Number of shares of Common Stock beneficially owned: Gilead - 31,424,760 shares Jeffrey A. Bluestone - 7,156 shares Percent of class: Gilead - 29.7% Jeffrey A. Bluestone - 0.01% The number of shares of Common Stock beneficially owned by Gilead consists of (i) 2,200,000 shares of Common Stock purchased in the 2020 Public Offering, (ii) the initial purchase of 5,963,029 shares of Common Stock pursuant to the Purchase Agreement, (iii) the subsequent purchase of 5,650,000 shares of Common Stock pursuant to the Amended and Restated Purchase Agreement, (iv) the subsequent purchase of 1,010,000 shares of Common Stock pursuant to the Second Amended and Restated Purchase Agreement, (v) the subsequent purchase of 15,238,095 shares of Common Stock pursuant to the Third Amended and Restated Purchase Agreement, and (vi) the subsequent purchase of 1,363,636 shares of Common Stock pursuant to the Public Offering. The number of shares of Common Stock beneficially owned by Mr. Bluestone consists of options to purchase 7,156 shares of Common Stock exercisable within 60 days. The percentage ownership for Gilead was calculated based upon 105,885,138 shares of common stock of the Issuer issued and outstanding as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 6, 2025. The percentage ownership for Mr. Bluestone was calculated based upon 105,892,294 shares of Common Stock issued and outstanding, based on 105,885,138 shares of Common Stock issued and outstanding and assuming the immediate exercise in full by Mr. Bluestone of his options. To the best knowledge of the Reporting Person, none of the individuals listed on Schedule I beneficially owns any of the Issuer's Common Stock, except Mr. Bluestone, who has received options to purchase shares of Common Stock in partial payment for his service on the Issuer's Scientific Advisory Board.

Item 5(b) of the Schedule 13D is hereby amended and restated to read as follows: Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: Gilead - 31,424,760 shares Jeffrey A. Bluestone - 7,156 shares (ii) Shared power to vote or to direct the vote: Gilead - 0 shares Jeffrey A. Bluestone - 0 shares (iii) Sole power to dispose or to direct the disposition of: Gilead - 31,424,760 shares Jeffrey A. Bluestone - 7,156 shares (iv) Shared power to dispose or to direct the disposition of: Gilead - 0 shares Jeffrey A. Bluestone - 0 shares